Weiss Ratings Reaffirms “Sell (D-)” Rating for Sera Prognostics (NASDAQ:SERA)

Sera Prognostics (NASDAQ:SERA)‘s stock had its “sell (d-)” rating restated by research analysts at Weiss Ratings in a research note issued on Saturday,Weiss Ratings reports.

Separately, Wall Street Zen raised Sera Prognostics from a “sell” rating to a “hold” rating in a research note on Saturday. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, Sera Prognostics has a consensus rating of “Sell”.

Sera Prognostics Price Performance

NASDAQ:SERA opened at $3.65 on Friday. Sera Prognostics has a 1 year low of $1.37 and a 1 year high of $9.13. The stock’s 50 day simple moving average is $3.09 and its two-hundred day simple moving average is $2.70. The company has a market cap of $137.51 million, a price-to-earnings ratio of -4.29 and a beta of 0.97.

Sera Prognostics (NASDAQ:SERA) last released its quarterly earnings data on Wednesday, August 6th. The company reported ($0.16) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.21) by $0.05. Sera Prognostics had a negative return on equity of 45.86% and a negative net margin of 30,306.48%.The business had revenue of $0.02 million for the quarter, compared to the consensus estimate of $0.05 million. As a group, analysts anticipate that Sera Prognostics will post -0.96 EPS for the current year.

Insider Buying and Selling at Sera Prognostics

In other news, CEO Zhenya Lindgardt sold 21,158 shares of the business’s stock in a transaction that occurred on Tuesday, September 9th. The stock was sold at an average price of $3.15, for a total transaction of $66,647.70. Following the transaction, the chief executive officer owned 811,136 shares of the company’s stock, valued at approximately $2,555,078.40. The trade was a 2.54% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Over the last 90 days, insiders sold 50,631 shares of company stock worth $153,604. Insiders own 13.50% of the company’s stock.

Hedge Funds Weigh In On Sera Prognostics

Several large investors have recently modified their holdings of SERA. Abel Hall LLC bought a new position in shares of Sera Prognostics during the 2nd quarter valued at approximately $31,000. Wagner Wealth Management LLC bought a new position in shares of Sera Prognostics during the 2nd quarter valued at approximately $34,000. Riverview Capital Advisers LLC bought a new position in shares of Sera Prognostics during the 2nd quarter valued at approximately $35,000. XTX Topco Ltd bought a new position in shares of Sera Prognostics during the 1st quarter valued at approximately $39,000. Finally, Birch Hill Investment Advisors LLC bought a new position in shares of Sera Prognostics during the 3rd quarter valued at approximately $84,000. Institutional investors own 54.64% of the company’s stock.

About Sera Prognostics

Sera Prognostics, Inc, a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies.